DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Sean McClain - 2 — - 1 McClain - 1 Tim Showalter - 1 Showalter - 1 it's - 1 Fred - 1 haven't - 1
Top related locs:
University of California San Diego Nagoya Japan China United States Brussels Belgium Swedish
Top related orgs:
Experts - 1 Service - 1 Northwestern Medicine - 1 Fred Hutchinson Cancer Center - 1 UW Medicine - 1 University of California - 1 Fujitsu - 1 Aichi Cancer - 1

Search resuls for: "Sean McClain"


2 mentions found


☆ AI is helping the healthcare industry and could transform the way patients get drugs and treatments
  + stars: | 2023-12-22 | by ( Nicholas Fearn | ) www.businessinsider.com   time to read: +10 min
In the pharmaceutical industry, AI may one day accelerate new-drug development. In the foreseeable future, McClain expects the healthcare industry to use AI technology to design personalized medicines. Risks to considerWhile AI offers promise for the healthcare industry, there are also a variety of risks professionals using AI must consider and mitigate. Showalter said that a lack of "comprehensive regulations" can also make using AI technology in healthcare settings risky. With this in mind, he said, the medical industry must understand the "fundamentals of AI and its applications in healthcare."
Persons: —, Sean McClain, McClain, Tim Showalter, Showalter, it's, Fred, haven't, Surya Josyula, Josyula Organizations: Experts, Service, Northwestern Medicine, Fred Hutchinson Cancer Center, UW Medicine, University of California, Fujitsu, Aichi Cancer, Fujitsu Laboratories of America Locations: University of California San Diego, Nagoya, Japan, China, United States
☆ AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
  + stars: | 2023-12-03 | by ( ) www.reuters.com   time to read: +1 min
The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease (COVID-19) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron/File Photo Acquire Licensing RightsCompanies Absci Corp FollowAstraZeneca PLC FollowDec 3 (Reuters) - Anglo-Swedish drugmaker AstraZeneca (AZN.L) has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci (ABSI.O) to design an antibody to fight cancer, the Financial Times reported on Sunday. The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said. Absci and AstraZeneca did not immediately respond to a Reuters requests for comment. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
Persons: Johanna Geron, Sean McClain, Absci’s, Shivani Tanna, William Mallard Organizations: AstraZeneca, REUTERS, U.S, Financial Times, Thomson Locations: Brussels, Belgium, Swedish, Bengaluru
0 next >>
Total: 2